Cardiol Therapeutics IncNASDAQ:CRDLView on Canadian Exchange
- LAST PRICE1.9000
- TODAY'S CHANGE (%)-0.0600 (-3.0612%)
- Bid / Lots1.9000/ 11
- Ask / Lots1.9100/ 1
- Open / Previous Close1.9200 / 1.9600
- Day Range
- 52 Week Range
- Volume80,993
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRDL |
|---|---|---|
| 09:32 ET | 2184 | 1.945 |
| 09:33 ET | 1500 | 1.94 |
| 09:37 ET | 1852 | 1.935 |
| 09:39 ET | 1008 | 1.91 |
| 09:42 ET | 400 | 1.9 |
| 09:44 ET | 100 | 1.9 |
| 09:48 ET | 31269 | 1.87 |
| 09:50 ET | 5186 | 1.92 |
| 09:51 ET | 812 | 1.91343 |
| 09:53 ET | 1000 | 1.9199 |
| 09:55 ET | 1000 | 1.915 |
| 09:57 ET | 1700 | 1.9435 |
| 10:00 ET | 400 | 1.94 |
| 10:02 ET | 500 | 1.94 |
| 10:04 ET | 1000 | 1.9433 |
| 10:06 ET | 560 | 1.93 |
| 10:08 ET | 418 | 1.94 |
| 10:22 ET | 6415 | 1.91 |
| 10:24 ET | 300 | 1.9 |
| 10:27 ET | 1000 | 1.905 |
| 10:29 ET | 300 | 1.9 |
| 10:31 ET | 599 | 1.9048 |
| 10:40 ET | 3100 | 1.9003 |
| 10:42 ET | 11251 | 1.88 |
| 10:44 ET | 272 | 1.8893 |
| 10:45 ET | 145 | 1.88 |
| 10:47 ET | 500 | 1.905 |
| 10:49 ET | 632 | 1.9 |
Oct 22, 2024
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis, from 6:32AM ET on Tuesday Oct 22, 2024 by Dow Jones
6:32AM ET on Tuesday Oct 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cardiol Therapeutics Inc | 218.1M | 0.0x | --- |
Company Information
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.
Contact Information
- Headquarters
- 602-2265 Upper Middle Road EastOAKVILLE, ON, Canada L6H 0G5
- Phone
- 289-910-0850
- Fax
- 905-491-6793
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $218.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.65 |
EPS | $-0.44 |
Book Value | $0.43 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
